Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H1 2018

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 39 molecules. Out of which approximately 36 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 10, 7, 11 and 3 respectively.

Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology and Respiratory which include indications Solid Tumor, Metastatic Melanoma, Breast Cancer, Gastric Cancer, Bladder Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Non-Small Cell Lung Cancer, Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastrointestinal Stromal Tumor (GIST), Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Ovarian Cancer, Bile Duct Cancer (Cholangiocarcinoma), Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Pancreatic Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Soft Tissue Sarcoma, Acral Lentiginous Melanoma, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Bone Metastasis, Brenner Tumor, Cancer Pain, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Endometrial Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gliosarcoma, Hematological Tumor, Inflammation, Lentigo Maligna Melanoma, Liposarcoma, Liver Cancer, Lung Adenocarcinoma, Malignant Ascites, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Hodgkin Lymphoma, Osteolysis, Osteosarcoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Uveal Melanoma and Von Hippel-Lindau Syndrome.

The latest report Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2018, outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
• The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope